PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - 'Nanobiotix” or the 'Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the 'Closing”) of its global offering (the 'Global Offering”), including in respect of the earlier total exercise by the underwriters of their option (the 'Option”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the 'Additional ADSs”).